AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,716,387 | +169.8% | 115,788 | +190.6% | 0.00% | – |
| Q1 2024 | $1,006,636 | +51.5% | 39,851 | +40.1% | 0.00% | – |
| Q4 2023 | $664,332 | -94.8% | 28,451 | -88.7% | 0.00% | -100.0% |
| Q3 2023 | $12,774,131 | +15.7% | 252,553 | +6.8% | 0.00% | 0.0% |
| Q2 2023 | $11,039,804 | +1446.9% | 236,449 | +1167.6% | 0.00% | – |
| Q1 2023 | $713,664 | -93.6% | 18,653 | -90.8% | 0.00% | -100.0% |
| Q4 2022 | $11,125,934 | +37.4% | 203,028 | -14.7% | 0.00% | 0.0% |
| Q3 2022 | $8,100,000 | +5300.0% | 237,886 | +2147.4% | 0.00% | – |
| Q1 2022 | $150,000 | -32.1% | 10,585 | +1.5% | 0.00% | – |
| Q4 2021 | $221,000 | -15.0% | 10,429 | -10.5% | 0.00% | – |
| Q3 2021 | $260,000 | +4.4% | 11,656 | +16.2% | 0.00% | – |
| Q2 2021 | $249,000 | – | 10,029 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 423,849 | $9,943,498 | 11.19% |
| Propel Bio Management, LLC | 327,752 | $7,689,062 | 4.99% |
| GENERAL ATLANTIC, L.P. | 5,233,989 | $122,789,382 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 625,087 | $14,664,541 | 3.46% |
| Yiheng Capital Management, L.P. | 1,434,179 | $33,645,839 | 2.71% |
| Redmile Group, LLC | 1,614,473 | $37,875,537 | 2.29% |
| Boxer Capital, LLC | 1,676,733 | $39,336,156 | 2.07% |
| RTW INVESTMENTS, LP | 5,431,985 | $127,434,368 | 1.97% |
| Logos Global Management LP | 800,000 | $18,768,000 | 1.52% |
| MPM BioImpact LLC | 385,990 | $9,055,325 | 1.41% |